Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890168749> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2890168749 endingPage "272" @default.
- W2890168749 startingPage "268" @default.
- W2890168749 abstract "Background: Oxidative stress and systemic inflammation is increased in end-stage renal disease (ESRD) patients. Due to the various effects of oxidative stress in ESRD patients, different antioxidants have been evaluated. Objectives: In this study, we evaluated the effect of oral N-acetylcysteine (NAC) as an antioxidant on the serum high-sensitive C-reactive protein (hs-CRP) and plasma hemoglobin levels in the ESRD patients who were under routine hemodialysis. Patients and Methods: In this randomized placebo-controlled clinical trial, 51 ESRD patients under routine hemodialysis were randomly assigned to receive NAC 1200 mg daily for 1 month (n=26) or placebo (n=25). Laboratory findings including hemoglobin, ferritin, hsCRP were measured in patients before and after treatment. Results: NAC group compared to placebo group had significantly higher ferritin levels before treatment (p=0.02) and lower phosphorus levels after treatment (p=0.03). Comparing the results before and after treatment in each group, a significant reduction in hematocrit (p=0.002), ferritin (p=0.006), hs-CRP (p=0.02) and an increase in alkaline phosphatase levels (p=0.005) in NAC group and significant reduction in calcium levels (p<0.001) in placebo group was detected. No major side effects were seen. Conclusions: One month treatment with oral NAC resulted in reduced levels of hematocrit, ferritin and Hs-CRP, indicative of role of NAC in controlling inflammation in ESRD patients under hemodialysis. However, NAC was not effective in treatment of anemia, although the treatment duration was low." @default.
- W2890168749 created "2018-09-27" @default.
- W2890168749 creator A5035522427 @default.
- W2890168749 creator A5052338777 @default.
- W2890168749 creator A5076223822 @default.
- W2890168749 creator A5077066663 @default.
- W2890168749 creator A5085505169 @default.
- W2890168749 date "2017-09-02" @default.
- W2890168749 modified "2023-10-14" @default.
- W2890168749 title "The effect of oral N-acetylcysteine on serum high sensitive CRP and plasma hemoglobin levels in end-stage renal disease patients under routine hemodialysis; a randomized placebocontrolled clinical trial" @default.
- W2890168749 doi "https://doi.org/10.15171/jnp.2018.53" @default.
- W2890168749 hasPublicationYear "2017" @default.
- W2890168749 type Work @default.
- W2890168749 sameAs 2890168749 @default.
- W2890168749 citedByCount "4" @default.
- W2890168749 countsByYear W28901687492020 @default.
- W2890168749 countsByYear W28901687492023 @default.
- W2890168749 crossrefType "journal-article" @default.
- W2890168749 hasAuthorship W2890168749A5035522427 @default.
- W2890168749 hasAuthorship W2890168749A5052338777 @default.
- W2890168749 hasAuthorship W2890168749A5076223822 @default.
- W2890168749 hasAuthorship W2890168749A5077066663 @default.
- W2890168749 hasAuthorship W2890168749A5085505169 @default.
- W2890168749 hasBestOaLocation W28901687491 @default.
- W2890168749 hasConcept C126322002 @default.
- W2890168749 hasConcept C146357865 @default.
- W2890168749 hasConcept C151730666 @default.
- W2890168749 hasConcept C168563851 @default.
- W2890168749 hasConcept C177713679 @default.
- W2890168749 hasConcept C185592680 @default.
- W2890168749 hasConcept C2777847592 @default.
- W2890168749 hasConcept C2778004101 @default.
- W2890168749 hasConcept C2778063415 @default.
- W2890168749 hasConcept C2778917026 @default.
- W2890168749 hasConcept C2779134260 @default.
- W2890168749 hasConcept C3019040382 @default.
- W2890168749 hasConcept C55493867 @default.
- W2890168749 hasConcept C71924100 @default.
- W2890168749 hasConcept C86803240 @default.
- W2890168749 hasConcept C90924648 @default.
- W2890168749 hasConceptScore W2890168749C126322002 @default.
- W2890168749 hasConceptScore W2890168749C146357865 @default.
- W2890168749 hasConceptScore W2890168749C151730666 @default.
- W2890168749 hasConceptScore W2890168749C168563851 @default.
- W2890168749 hasConceptScore W2890168749C177713679 @default.
- W2890168749 hasConceptScore W2890168749C185592680 @default.
- W2890168749 hasConceptScore W2890168749C2777847592 @default.
- W2890168749 hasConceptScore W2890168749C2778004101 @default.
- W2890168749 hasConceptScore W2890168749C2778063415 @default.
- W2890168749 hasConceptScore W2890168749C2778917026 @default.
- W2890168749 hasConceptScore W2890168749C2779134260 @default.
- W2890168749 hasConceptScore W2890168749C3019040382 @default.
- W2890168749 hasConceptScore W2890168749C55493867 @default.
- W2890168749 hasConceptScore W2890168749C71924100 @default.
- W2890168749 hasConceptScore W2890168749C86803240 @default.
- W2890168749 hasConceptScore W2890168749C90924648 @default.
- W2890168749 hasIssue "4" @default.
- W2890168749 hasLocation W28901687491 @default.
- W2890168749 hasOpenAccess W2890168749 @default.
- W2890168749 hasPrimaryLocation W28901687491 @default.
- W2890168749 hasRelatedWork W1592667025 @default.
- W2890168749 hasRelatedWork W2054921653 @default.
- W2890168749 hasRelatedWork W2073276413 @default.
- W2890168749 hasRelatedWork W2098843574 @default.
- W2890168749 hasRelatedWork W2144689877 @default.
- W2890168749 hasRelatedWork W2417550195 @default.
- W2890168749 hasRelatedWork W2419447267 @default.
- W2890168749 hasRelatedWork W2887403370 @default.
- W2890168749 hasRelatedWork W4226471102 @default.
- W2890168749 hasRelatedWork W4234406362 @default.
- W2890168749 hasVolume "7" @default.
- W2890168749 isParatext "false" @default.
- W2890168749 isRetracted "false" @default.
- W2890168749 magId "2890168749" @default.
- W2890168749 workType "article" @default.